(Q28264146)

https://api.crossref.org/works/10.1038/NRC1367

Targeting HIF-1 for cancer therapy

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/NRC1367

Combination bacteriolytic therapy for the treatment of experimental tumors

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/NRC1367

Hypoxia--a key regulatory factor in tumour growth

21 April 2017

1 reference

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

21 April 2017

1 reference

The histological structure of some human lung cancers and the possible implications for radiotherapy

21 April 2017

1 reference

The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy

31 March 2020

1 reference

Clinical trials of radiosensitizers: What should we expect?

31 March 2020

1 reference

Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck

31 March 2020

1 reference

Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome

31 March 2020

1 reference

Conventional cancer therapy: promise broken or promise delayed?

31 March 2020

1 reference

The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour

31 March 2020

1 reference

Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species

31 March 2020

1 reference

Mutagenesis induced by the tumor microenvironment

31 March 2020

1 reference

Microenvironment-induced cancer metastasis

31 March 2020

1 reference

The hypoxic tumour microenvironment and metastatic progression

31 March 2020

1 reference

SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells

31 March 2020

1 reference

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours

31 March 2020

1 reference

A mass spectrometry study of tirapazamine and its metabolites. insights into the mechanism of metabolic transformations and the characterization of reaction intermediates

31 March 2020

1 reference

Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction

31 March 2020

1 reference

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin

31 March 2020

1 reference

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

31 March 2020

1 reference

Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent

31 March 2020

1 reference

Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy

31 March 2020

1 reference

Tumour cytochrome P450 and drug activation

31 March 2020

1 reference

AQ4N: a new approach to hypoxia-activated cancer chemotherapy

31 March 2020

1 reference

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent

31 March 2020

1 reference

Hypoxia-Specific Cytotoxins in Cancer Therapy

31 March 2020

1 reference

Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors

31 March 2020

1 reference

Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).

31 March 2020

1 reference

Recent advances in bioreductive drug targeting

31 March 2020

1 reference

Bioreductive therapies: an overview of drugs and their mechanisms of action

31 March 2020

1 reference

The experimental development of bioreductive drugs and their role in cancer therapy.

31 March 2020

1 reference

Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting

31 March 2020

1 reference

DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine

31 March 2020

1 reference

Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors

31 March 2020

1 reference

Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs

31 March 2020

1 reference

Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt(III)-nitrogen mustard complex SN 24771

31 March 2020

1 reference

Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice

31 March 2020

1 reference

Identification of a hypoxic population of bone marrow cells

31 March 2020

1 reference

Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.

31 March 2020

1 reference

Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents.

31 March 2020

1 reference

Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine

31 March 2020

1 reference

Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: a key factor in controlling hypoxia-selective drug release

31 March 2020

1 reference

Pathways of reductive fragmentation of heterocyclic nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine

31 March 2020

1 reference

Optimization of the auxiliary ligand shell of Cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs.

31 March 2020

1 reference

A novel class of antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), that releases 5-fluorouracil upon hypoxic irradiation

31 March 2020

1 reference

The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages

31 March 2020

1 reference

Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes

31 March 2020

1 reference

Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives

31 March 2020

1 reference

Hypoxia-mediated tumour targeting

31 March 2020

1 reference

Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy

31 March 2020

1 reference

Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

31 March 2020

1 reference

Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.

31 March 2020

1 reference

The macrophage - a novel system to deliver gene therapy to pathological hypoxia

31 March 2020

1 reference

Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy

31 March 2020

1 reference

HIF-1 as a target for drug development

31 March 2020

1 reference

Suppression of tumor growth through disruption of hypoxia-inducible transcription

31 March 2020

1 reference

Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy

31 March 2020

1 reference

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

31 March 2020

1 reference

YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.

31 March 2020

1 reference

Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment

31 March 2020

1 reference

The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium

31 March 2020

1 reference

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma

31 March 2020

1 reference

Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis

31 March 2020

1 reference

Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.

31 March 2020

1 reference

Clostridia in cancer therapy

31 March 2020

1 reference

Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial

31 March 2020

1 reference

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice

31 March 2020

1 reference

Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid

31 March 2020

1 reference

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

31 March 2020

1 reference

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.

31 March 2020

1 reference

Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers

31 March 2020

1 reference

2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256.

31 March 2020

1 reference

A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells

31 March 2020

1 reference

The nitroreductase enzyme in walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)

31 March 2020

1 reference

The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT).

31 March 2020

1 reference

Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide)

31 March 2020

1 reference

Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells

31 March 2020

1 reference

Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors.

31 March 2020

1 reference

Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue.

31 March 2020

1 reference

Measurement of Human Tumour Oxygenation Status by a Polarographic Needle Electrode: An analysis of inter- and intratumour heterogeneity

31 March 2020

1 reference

Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue

31 March 2020

1 reference

Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients

31 March 2020

1 reference

Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications

31 March 2020

1 reference

Pancreatic tumors show high levels of hypoxia

31 March 2020

1 reference

Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia

31 March 2020

1 reference

Oxygenation predicts radiation response and survival in patients with cervix cancer

31 March 2020

1 reference

Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas

31 March 2020

1 reference

Hypoxia in human prostate carcinoma: an Eppendorf PO2 study.

31 March 2020

1 reference

The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC1367

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

86312

1052255963

0 references

86312

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference